Avalon Pharmaceuticals to Present on Its Beta-catenin and c-Myc Pathway Inhibitor Programs at the AACR-NCI-EORTC 2007 International Conference
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it would be presenting four posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2007, in San Francisco, CA.
The posters to be presented by Avalon will describe program success against two of the most clinically relevant and historically “undruggable” pathways in cancer: Beta-catenin and c-Myc. The posters are titled:
“Compounds selected and optimized from a biomarker based Beta-catenin pathway screen decrease Beta-catenin protein levels in xenograft tumors, induce a gene expression signature consistent with inhibition of beta-catenin activity, and exhibit anti tumor growth properties.” Presentation time: Thursday, October 25, 2007, from 12:30pm-2:30pm and from 5:30pm-7:30pm (PST).
“LC-363: Optimization and in vitro characterization of a novel series of small molecule inhibitors of the Wnt/Beta-catenin signaling pathway.” Presentation time: Thursday, October 25, 2007, from 12:30pm-2:30pm and from 5:30pm-7:30pm (PST).
“A biomarker based high throughput screen identifies small molecular weight modulators of the Beta-catenin pathway.” Presentation time: Tuesday, October 23, 2007, from 12:30pm-2:30pm and from 5:30pm-7:30pm p.m. (PST).
“Biomarker based high-throughput screening for identification of small molecule inhibitors, targeting the antiproliferative property of the c-Myc signaling pathway.” Presentation time: Tuesday, October 23, 2007, from 12:30pm-2:30pm and from 5:30pm-7:30pm p.m. (PST).
About Avalon Pharmaceuticals
Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon’s lead product candidate, AVN944, an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways, discovery programs for inhibitors of the Survivin and Myc pathways and partnerships with Merck, MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx® is the company’s proprietary platform which is based on large-scale biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable." Avalon is headquartered in Germantown, Md.
surf's up......crikey
